A detailed history of Rhumbline Advisers transactions in Natera, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 133,540 shares of NTRA stock, worth $15.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
133,540
Previous 145,537 8.24%
Holding current value
$15.1 Million
Previous $9.12 Million 33.97%
% of portfolio
0.01%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

SELL
$59.21 - $92.9 $710,342 - $1.11 Million
-11,997 Reduced 8.24%
133,540 $12.2 Million
Q4 2023

Feb 08, 2024

BUY
$37.55 - $62.64 $156,470 - $261,020
4,167 Added 2.95%
145,537 $9.12 Million
Q3 2023

Nov 09, 2023

BUY
$43.4 - $62.52 $77,555 - $111,723
1,787 Added 1.28%
141,370 $6.26 Million
Q2 2023

Aug 08, 2023

BUY
$47.08 - $55.16 $973,143 - $1.14 Million
20,670 Added 17.38%
139,583 $6.79 Million
Q1 2023

May 11, 2023

BUY
$36.57 - $58.29 $433,976 - $691,727
11,867 Added 11.09%
118,913 $6.6 Million
Q4 2022

Feb 14, 2023

BUY
$34.17 - $47.91 $354,513 - $497,066
10,375 Added 10.73%
107,046 $4.3 Million
Q3 2022

Nov 10, 2022

BUY
$36.93 - $56.68 $308,624 - $473,674
8,357 Added 9.46%
96,671 $4.24 Million
Q2 2022

Aug 11, 2022

BUY
$28.13 - $44.54 $243,549 - $385,627
8,658 Added 10.87%
88,314 $3.13 Million
Q1 2022

May 12, 2022

SELL
$30.32 - $91.33 $203,598 - $613,280
-6,715 Reduced 7.77%
79,656 $3.24 Million
Q4 2021

Feb 10, 2022

BUY
$86.26 - $119.0 $305,101 - $420,903
3,537 Added 4.27%
86,371 $8.07 Million
Q3 2021

Nov 12, 2021

BUY
$100.17 - $126.36 $383,550 - $483,832
3,829 Added 4.85%
82,834 $9.23 Million
Q2 2021

Aug 05, 2021

SELL
$86.05 - $119.72 $1.12 Million - $1.56 Million
-13,028 Reduced 14.16%
79,005 $8.97 Million
Q1 2021

May 06, 2021

SELL
$91.47 - $124.36 $771,915 - $1.05 Million
-8,439 Reduced 8.4%
92,033 $9.35 Million
Q4 2020

Feb 10, 2021

BUY
$66.66 - $111.74 $493,950 - $827,993
7,410 Added 7.96%
100,472 $10 Million
Q3 2020

Nov 12, 2020

SELL
$45.89 - $72.67 $923,031 - $1.46 Million
-20,114 Reduced 17.77%
93,062 $6.72 Million
Q2 2020

Aug 13, 2020

BUY
$26.36 - $49.86 $595,867 - $1.13 Million
22,605 Added 24.96%
113,176 $5.64 Million
Q1 2020

May 06, 2020

BUY
$17.27 - $40.17 $52,259 - $121,554
3,026 Added 3.46%
90,571 $2.7 Million
Q4 2019

Feb 05, 2020

BUY
$32.1 - $40.4 $339,553 - $427,351
10,578 Added 13.74%
87,545 $2.95 Million
Q3 2019

Oct 23, 2019

BUY
$25.38 - $34.89 $54,795 - $75,327
2,159 Added 2.89%
76,967 $2.53 Million
Q2 2019

Aug 14, 2019

BUY
$17.75 - $27.58 $550,250 - $854,980
31,000 Added 70.76%
74,808 $2.06 Million
Q1 2019

May 01, 2019

SELL
$11.34 - $20.62 $3,209 - $5,835
-283 Reduced 0.64%
43,808 $903,000
Q4 2018

Jan 31, 2019

BUY
$12.32 - $24.38 $187,510 - $371,063
15,220 Added 52.72%
44,091 $616,000
Q3 2018

Nov 07, 2018

SELL
$18.82 - $28.96 $9,165 - $14,103
-487 Reduced 1.66%
28,871 $691,000
Q2 2018

Aug 06, 2018

BUY
$8.79 - $19.98 $1,529 - $3,476
174 Added 0.6%
29,358 $553,000
Q1 2018

May 02, 2018

SELL
$9.0 - $11.95 $1,755 - $2,330
-195 Reduced 0.66%
29,184 $271,000
Q4 2017

Feb 09, 2018

SELL
$8.99 - $14.31 $49,885 - $79,406
-5,549 Reduced 15.89%
29,379 $264,000
Q3 2017

Nov 06, 2017

BUY
$8.02 - $13.33 $280,122 - $465,590
34,928
34,928 $450,000

Others Institutions Holding NTRA

About Natera, Inc.


  • Ticker NTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 96,957,400
  • Market Cap $10.9B
  • Description
  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...
More about NTRA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.